Evidence map›Paper›PMID 37808844›Full record

ArticlebioRxiv : the preprint server for biology2023

Replication-dead gammaherpesvirus vaccine protects against acute replication, reactivation from latency, and lethal challenge in mice.

Wesley A Bland, Shana Owens, Kyle McEvoy, Chad H Hogan, Luciarita Boccuzzi, Varvara Kirillov, Camille Khairallah, Brian S Sheridan, J Craig Forrest, Laurie T Krug

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Wesley A BlandDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Shana OwensDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Kyle McEvoyDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Chad H HoganGraduate Program in Genetics, Stony Brook University, Stony Brook, New York, USA.
Luciarita BoccuzziHIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA.
Varvara KirillovDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Camille KhairallahDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Brian S SheridanDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
J Craig ForrestDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Laurie T KrugDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Stony Brook University · USNational Cancer Institute · USUniversity of Arkansas for Medical Sciences · USWinthrop Rockefeller Foundation · US

Funding

Gammaherpesvirus interactions with host tumor suppressor p53R01CA167065 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI James Craig Forrest · 2014 to 2026
$3.8M
J. NRSA TrainingTL1TR003109 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI SEXTON, KEVIN WAYNE · 2019 to 2023
$1.5M
Defining the efficacy of replication-dead viruses as gammaherpesvirus vaccinesR21AI139580 · NIAID · UNIV OF ARKANSAS FOR MED SCIS · PI FORREST, JAMES CRAIG · 2019 to 2020
$440k
NCATS NIH HHS TL1 TR003109NCI NIH HHS R01 CA167065NIAID NIH HHS R21 AI139580
6 · The paper itself

Abstract

Gammaherpesviruses (GHVs) are oncogenic viruses that establish lifelong infections and are significant causes of human morbidity and mortality. While several vaccine strategies to limit GHV infection and disease are in development, there are no FDA-approved vaccines for human GHVs. As a new approach to gammaherpesvirus vaccination, we developed and tested a replication-dead virus (RDV) platform, using murine gammaherpesvirus 68 (MHV68), a well-established mouse model for gammaherpesvirus pathogenesis studies and preclinical therapeutic evaluations. We employed codon-shuffling-based complementation to generate revertant-free RDV lacking expression of the essential replication and transactivator protein (RTA) encoded by

Indexed as

antibodyeffector T cellgammaherpesvirusimmune responseinterferonlatencylytic replicationmemory T cellreplicationreplication-defectivevaccineviral pathogenesis

Identifiers

PMID37808844
PMCPMC10557649
OpenAlexW4387102752

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.